STING1 and neoplasm: Systemic injection of a low-dose LID followed by US treatment over the tumor was able to induce targeted tumor killing and STING activation in the tumor, resulting in potent antitumor T cell immunity, which upon the combination with αPD-L1, regressed multiple types of tumors and protected animals from relapse (Fig. 8).